Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C09DA04

Ifirmacombi(irbesartan;hydrochlorothiazide)

Hypertension

Marketing Authorisation Holder: Krka, d.d., Novo mesto

EMA Authorisation: 04/03/2011

INN: irbesartan;hydrochlorothiazide

Indication

Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ifirmacombi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.